Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. bloodstemplus

BloodStemPLUS

Commercial feasibility study of a technology that multiplies blood stem cells to increase the success of transplants for cancer treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 BloodStemPLUS project word cloud

Explore the words cloud of the BloodStemPLUS project. It provides you a very rough idea of what is the project "BloodStemPLUS" about.

trial    validation    enormous    death    compliance    invest    company    maintenance    limited    12    reimbursement    compromise    multiplies    nature    cell    business    start    quality    20x    expansion    stem    owns    15    assuring    record    plan    preparing    stemcell2max    ing    2020    route    investor    horizon    cancer    usa    summit    cord    commercialisation    limitations    cagr    won    scientific    patients    clinical    policies    33    acceptance    explore    multiplication    transplants    investable    track    donor    japan    protected    outcomes    published    600m    2015    4b    market    proprietary    markets    34    biotechnology    hospitals    global    banks    november    regulatory    innovation    sales    multiplying    lack    demand    scarce    strategic    partnering    purposes    treatment    cells    solution    patient    award    blood    500    marketing    strategy    billion    optimal    requirements    groups    first    transplantation    recognition   

Project "BloodStemPLUS" data sheet

The following table provides information about the project.

Coordinator		 GROWINGFORMULA LDA 

Organization address
address: BIOCANT PARK NUCLEO 04, LOTE 02
city: CANTANHEDE
postcode: 3060 197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Portugal [PT]
 Project website http://www.stemcell2max.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GROWINGFORMULA LDA PT (CANTANHEDE) coordinator 50˙000.00

Map

 Project objective

StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but are scarce resulting in limited transplants (34% of patients do not find a donor), patient death (6-15%) and limitations at research level (12.500 groups lack cells for their studies). StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers in an estimated €3 billion potential market (33% CAGR).

No solution for blood stem cell multiplication is available for clinical purposes and those that are currently used for research purposes compromise cell quality. StemCell2MAX has developed a product that multiplies these cells while assuring their quality (20x better results compared to state of the art, as published in Nature).

Currently, StemCell2MAX markets a research use only product (€600M market) with a growing sales track record, both in EU and USA. Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing their solution for the €2.4B clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use. StemCell2MAX won the “most investable company” award during the first Horizon 2020 – Invest Horizon Global Investor Summit in November 2015.

Specific objectives: • To develop a business plan and marketing strategy for clinical application • To explore strategic partnerships for development and commercialisation • To explore the clinical validation strategy/clinical trial design • To develop a strategic development plan in agreement with reimbursement policies

Expected outcomes: • A business plan and optimal route-to-market, including partnering strategy for further development • Clinical trial strategy in compliance with all regulatory requirements

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BLOODSTEMPLUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BLOODSTEMPLUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More